/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
/CASE REPORTS/ Whack is a new psychoactive substance available until recently in head shops. It contains two active constituents, 4-fluorotropacocaine and desoxypipradrol. We present two case reports of subjects who developed acute psychotic states after using Whack. Both individuals displayed similar affective and anxiety symptoms in the presence of significant psychotic symptoms. Both required inpatient treatment but displayed a good treatment response to atypical antipsychotic agents.
/SURVEILLANCE/ In August 2010 the UK National Poisons Information Service received many enquiries relating to a recreational 'legal high' called 'Ivory Wave'. Although previously reported to contain methylenedioxypyrovalerone (MDPV) and lignocaine, the constituents of these recent Ivory Wave batches was unknown. Here we describe clinical features and analytical information obtained from recent users. Between 2nd and 23rd August 2010, 26 patients (19 male, 7 female, aged 16 to 40 years) presented to the Emergency Departments of the Royal Infirmary of Edinburgh (n=19) and Frimley Park Hospital (n=7). The interval since exposure, when reported (n=20), ranged from 3 hours to 1 week. Undesirable psychiatric effects were observed in 25 (96%) patients, including hallucinations (58%), insomnia (46%), agitation (38%), paranoia (23%), anxiety (15%), restlessness and aggression (each 4%). Tachycardia (73%), palpitations (8%), chest pain (4%), raised creatine kinase (62%) and movement abnormalities (e.g. dystonia, hemiballismus and akathisia, 27%) were also reported. Marked livido reticularis was seen in one patient; this had not resolved completely after two days. Analysis of a sample of the 'Ivory Wave' product associated with the Edinburgh cases confirmed the presence of desoxypipradrol (2-diphenylmethylpiperidine, 2-DPMP) but not MDPV or other active compounds. Biological samples from these Edinburgh cases all contain desoxypipradrol. Ivory Wave exposure was associated with marked psychiatric and neurological effects, together with cardiovascular features and evidence of muscle toxicity. Analysis is not available for all cases, but when performed confirms the presence of 2-DPMP. The reported psychiatric features resemble those described in Ireland after exposure to 'whack', also found to contain 2-DPMP with flourotropacocaine. In response to this apparent increasing recreational use, an import ban for 2-DPMP was introduced in the UK on 4th November 2010.
[EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
申请人：ARENA PHARM INC
公开号：WO2017023679A1
公开（公告）日：2017-02-09
Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.
Novel heterogeneous catalysts were prepared by impregnation of titania with a solution of cobalt acetate/melamine and subsequent pyrolysis. The resulting materials show an unusual nitrogen‐modified titanium structure through partial implementation of nitrogen into the support. The optimal catalyst displayed good activity and selectivity for challenging pyridinehydrogenation under acid free conditions
[EN] NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2<br/>[FR] MODULATEURS ALLOSTÉRIQUES NÉGATIFS DU RÉCEPTEUR MÉTABOTROPIQUE DU GLUTAMATE DE TYPE 2
申请人：UNIV VANDERBILT
公开号：WO2016149324A1
公开（公告）日：2016-09-22
Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
This invention aims at providing a catalyst for producing an optically active aldehyde or an optically active ketone, which is an optically active carbonyl compound, by carrying out selective asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, particularly a catalyst which is insoluble in a reaction mixture for obtaining optically active citronellal which is useful as a flavor or fragrance, by carrying out selective asymmetric hydrogenation of citral, geranial or neral; and a method for producing a corresponding optically active carbonyl compound. The invention relates to a catalyst for asymmetric hydrogenation of an α,β-unsaturated carbonyl compound, which comprises a powder of at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table, or a metal-supported substance in which at least one metal selected from metals belonging to Group 8 to Group 10 of the Periodic Table is supported on a support, an optically active cyclic nitrogen-containing compound and an acid.
